Please login to the form below

Not currently logged in
Email:
Password:

Ryzodeg

This page shows the latest Ryzodeg news and features for those working in and with pharma, biotech and healthcare.

Novo seeks to strengthen Tresiba label in US

Novo seeks to strengthen Tresiba label in US

Interim results from the 7, 500-patient DEVOTE study were instrumental in allowing Novo to get FDA approval for Tresiba and combination drug Ryzodeg in 2015, after being knocked back by

Latest news

  • Novo Nordisk's Tresiba gaining ground in basal insulin market Novo Nordisk's Tresiba gaining ground in basal insulin market

    Nevertheless, the strong sales performance for Tresiba and other new insulin products - such as combination products Ryzodeg (insulin degludec/insulin aspart) and Xultophy (insulin degludec/liraglutide) - helped Novo Nordisk post a

  • Tresiba safer than insulin glargine, says Novo Nordisk Tresiba safer than insulin glargine, says Novo Nordisk

    Last October however the Danish drugmaker finally won US approval for Tresiba and combination product Ryzodeg (insulin degludec and insulin aspart), prompting analysts at Sydbank to increase their peak sales predictions

  • Novo Nordisk finally bags insulin degludec approval in US Novo Nordisk finally bags insulin degludec approval in US

    Ryzodeg, two drugs expected to consolidate its position as the leading diabetes company. ... Earlier this year however Novo Nordisk decided to refile Tresiba and Ryzodeg on the strength of interim data from the outcomes trial, called DEVOTE.

  • Novo brings Xultophy to third European market Novo brings Xultophy to third European market

    US regulators dealt the company a major blow in February 2013 when marketing applications for Tresiba and Ryzodeg, which combines Tresiba with Novo's Novolog (insulin aspart), were rejected.

  • Novo Nordisk opens insulin facility in Russia Novo Nordisk opens insulin facility in Russia

    Last month, the firm revealed plans to resubmit its FDA marketing applications for diabetes therapies Tresiba and Ryzodeg after being rejected two years ago, with the regulatory body beginning its revaluation

More from news
Approximately 6 fully matching, plus 14 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...